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Abstract 
Background: Bovine leukemia virus (BLV) is the causative agent of enzootic bovine leukosis, the most common neo‑
plastic disease of cattle. BLV is closely related to human T cell leukemia virus. B cell epitopes are important for the use 
of antibodies as therapeutic agents, the epitope‑driven vaccine design, and immunological assays. A common B cell 
epitope for BLV has not yet been found due to individual differences in disease susceptibility.
Results: We used a peptide microarray with 156 synthetic 15‑mer peptides covering the envelope glycoprotein gp51 
and the Gag proteins p15, p24, and p12 to map B cell epitope and one B cell epitope, gp51p16, was recognized by 
all four cattle experimentally infected with BLV. A newly developed high‑throughput peptide ELISA system revealed 
590 (91.2 %) of 647 cattle naturally infected with BLV, carrying 25 different bovine leukocyte antigen class II DRB3 
(BoLA‑DRB3) alleles, responded to a 20‑mer gp51p16‑C peptide containing a C‑terminal cysteine and gp51p16. Ala‑
nine mutation and comparison of the sequences at 17 amino acid positions within gp51p16‑C revealed that R7, R9, 
F10, V16, and Y18 were the common binding sites to BLV antibodies, and two of these sites were found to be highly 
conserved. Transient expression in the cells of five infectious molecular clones of BLV with a single alanine mutation 
at five common antibody binding sites had no effect syncytia formation of the gp51 protein. In addition, the mutant 
proteins, R7A and R9A had no effect on the expression of gp51 protein; the gp51 protein expressions of F10A, V16A 
and Y18A were lower than that of the wild type protein.
Conclusions: This is the first report to identify a common B cell epitope in BLV by comprehensive screening of BLV‑
infected cattle with varied genetic backgrounds in BoLA‑DRB3. Our results have important implications for disease 
control and diagnosis.
Keywords: Bovine leukemia virus, Common B cell epitope, Comprehensive screening, Peptide microarray, Peptide 
ELISA high‑throughput system, Antibody binding site, Bovine leukocyte antigen class II
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Background
Bovine leukemia virus (BLV) is the etiologic agent of 
enzootic bovine leukosis (EBL), the most common neo-
plastic disease of cattle, and is closely related to human 
T cell leukemia virus type 1 and 2 (HTLV-1 and HTLV-2) 
[1–3]. BLV is highly prevalent in several regions of the 
world and induces major economic losses in cattle pro-
duction and export [4]. Erskine and Bartlett et  al. had 
reported BLV infection is associated with herd-level in 
high-performing dairy herds and cow longevity [5, 6]. 
In 1995, losses in the dairy industry due to BLV from 
USA were estimated to be $US 525 million annually [4]. 
Recently study had been reported the economic losse per 
case of lymphosarcoma was estimated to be $412 [7].
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BLV expresses the structural gag, pol, and env genes 
that are required for viral particle synthesis [8–10]. The 
gag gene of BLV is translated as the precursor Pr45 Gag 
and is processed into three mature proteins [8, 11]: the 
matrix protein p15 that binds genomic viral RNA and 
interacts with the lipid bilayer of the viral membrane [12]; 
the capsid protein p24 that is the major target for the host 
immune response with high antibody titers found in the 
serum of infected animals [13, 14]; and the nucleocap-
sid protein p12 that binds to the packaged genomic RNA 
[15]. The env gene encodes a mature surface glycopro-
tein (gp51) and a transmembrane protein (gp30) [8]. The 
N-terminal half of mature BLV gp51 plays an important 
role in viral infectivity and syncytium formation [16–18].
Virus factors and host factors are believed to determine 
disease progression in chronic infectious diseases such as 
acquired immunodeficiency syndrome (AIDS), HTLV-
associated diseases, and BLV-induced EBL [19]. One of 
the most important host factors is the polymorphism 
of the major histocompatibility complex (MHC). In cat-
tle, the MHC system is known as the bovine leukocyte 
antigen (BoLA) system and is a highly polymorphic and 
tightly linked gene cluster [20]. There is one predominant 
class II DRB locus in cattle, namely, BoLA-DRB3 [21], 
and this locus is the most polymorphic class II locus in 
cattle. To date, 132 alleles have been registered on the 
Immuno Polymorphism Database (IPD)-MHC database 
(http://www.ebi.ac.uk/ipd/mhc/bola). It has been sug-
gested that the BoLA-DRB3 gene may play a direct role 
in controlling the number of BLV-infected peripheral B 
lymphocytes in vivo in Holstein cattle [22, 23]. Moreover, 
the BoLA-DRB3*0902 and BoLA-DRB3*1101 polymor-
phisms were reported to be associated with a low proviral 
load (LPVL), and BoLA-DRB3*1601 was associated with 
a high proviral load (HPVL) in Japanese Black cattle [24]. 
Thus, individual differences in cattle against BLV disease 
progression are believed to be determined by highly poly-
morphic BoLA class II alleles.
By epitope mapping using cattle with experimentally 
infected BLV and a library of overlapping peptides of BLV, 
we identified CD8+ cytotoxic T lymphocyte epitopes [25] 
and CD4+ T cell epitopes (Unpublished Data) that were 
found to differ from those previously identified in cattle, 
mice, and sheep [17, 26–29]. Therefore, we hypothesized 
that not only animal species but also individual differ-
ences affect BLV epitopes. T cell epitopes of BLV have 
been identified in previous studies [17, 26–29], and these 
epitopes have been not found as a common epitope for 
all BLV-infected cattle. The large individual differences 
in BLV immunoreactivity pose a major challenge in the 
development of a vaccine against BLV.
Previous studies have reported that humoral immunity 
is induced in earlier phases of infection in BLV-infected 
animals [30–33]. The B cells of the immune system rec-
ognize the pathogen’s antigens by their membrane-bound 
immunoglobulin receptors and, in response, produce 
antibodies specific to these antigens; antibodies bind to 
antigens at specific sites that correspond to the antigenic 
determinants or B cell epitopes [34–36]. Therefore, iden-
tification and characterization of common B cell epitopes 
in target antigens is a key step in antibody production, 
epitope-driven vaccine design, and immunodiagnos-
tic tests. In the present study, identification of a com-
mon B cell epitope in BLV among a large population of 
BLV-infected cattle with varied genetic backgrounds in 
BoLA-DRB3 alleles was investigated. First, 156 synthetic 
peptides that covered the entire Gag protein and gp51 
protein sequence were prepared for the identification of 
common B cell epitopes in BLV that respond to all four 
cattle experimentally infected with BLV via a peptide 
microarray that was highly specific to the antigen–anti-
body response. Second, a new high-throughput peptide 
enzyme-linked immunosorbent assay (ELISA) system 
was established for confirmation of whether the iden-
tified B cell epitope was common via analysis of serum 
samples from cattle carrying 25 different BoLA-DRB3 
alleles. Third, the possible common binding sites to BLV 
antibodies were determined using variants harboring 
a single alanine mutation on each amino acid position 
within the common B cell epitope. Fourth, the effects 
of alanine substitution of a common binding site within 
the common B cell epitope on viral expression and fuso-
genicity were examined by reverse genetics of an infec-
tious molecular clone of BLV, pBLV-IF [37, 38]. Finally, 
the conservation of each amino acid within the common 
B cell epitope was examined.
Results
Identification of a common B cell epitope via a 
high‑throughput peptide ELISA system
To identify a B cell epitope in BLV, 156 synthetic pep-
tides of 15 amino acids in length that were derived 
from the whole BLV Gag proteins, p12, p24, and p15, 
and the Env gp51 protein, were prepared, followed by 
peptide microarray [39]. Using peptide microarray, the 
responses between the negative and positive serum 
samples obtained before and after experimental infec-
tion of four cattle, JBS4, JBS6, JBN1, and JBN2, that car-
ried the BoLA-DRB3*1601, *1501, *2703, or *0503 alleles 
(Table  1), resulted in the detection of B cell epitopes 
that responded with the positive serum from each cat-
tle (Table 3). Only one B cell epitope was recognized by 
all of the experimentally infected cattle and was termed 
gp51p16, reasons for individual difference in disease sus-
ceptibility against BLV that may be associated with poly-
morphisms of the BoLA-DRB3 gene.
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To clarify whether gp51p16 is a common B cell epitope, 
a new high-throughput peptide ELISA system utilizing 
maleimide-activated carrier protein mcKLH linked with 
the thioether bond of the terminal cysteine of gp51p16-
C that was modified as a C-terminal cysteine-contain-
ing 20-mer peptide to fix gp51p16 on a mcKLH-coated 
microplate was developed. Comprehensive screening 
of serum samples obtained from 647 cattle naturally 
infected with BLV that shared 25 different BoLA-DRB3 
alleles and 270 BLV non-infected cattle that shared 23 
different BoLA-DRB3 alleles were performed (Table  2). 
The 20 alleles were same among the non-infected group 
and infected group. We have defined the line of positive 
response by histogram analysis using 917 serum sam-
ples (Fig. 1a). The frequency of negative samples mostly 
declined and crossed with positive samples’ was as 
determination point, and that OD value was 0.3. In 590 
(91.2  %) of 647 serum samples, gp51p16-C was found 
to be positive in cattle that were positive for anti-BLV 
antibody using an anti-BLV ELISA kit and BLV provirus 
using BLV-CoCoMo-qPCR-2 (Fig.  1). These results sug-
gest that gp51p16-C contains a common B cell epitope in 
a large number of cattle naturally infected with BLV car-
rying 25 different BoLA-DRB3 alleles.
Binding site of the B cell epitope with BLV antibodies
Antigen–antibody interactions play a pivotal role in 
the humoral immune response [35, 40]. To determine 
binding sites with BLV antibodies within the common 
epitope gp51p16-C, 17 variants harboring single ala-
nine substitutions at each amino acid position within 
gp51p16-C were synthesized and named W1A to D19A, 
respectively (Fig. 2a). BLV positive serum was examined 
via a new high-throughput peptide ELISA system using 
these variants.
Figure  2b demonstrates the SI of BLV positive serum 
samples that were obtained from four cattle experimen-
tally infected with BLV for each single alanine variant. 
The SI values of the P2A, P3A, P4A, Q5A, R8A, G11A, 
R13A, and D19A variants against the four BLV positive 
serum samples were observed higher than value of no 
peptide. By contrast, the W1A, G6A, R7A, R9A, F10A, 
M15A, V16A, T17A, and Y18A variants were found 
to have similar (same or less than) value of no peptide 
against the four BLV positive serum samples.
As shown in Fig. 2c, responses against four BLV posi-
tive serums of the 17 single alanine variants were further 
confirmed using a number of serum samples from cattle 
naturally infected with BLV (Table 2). The variants R7A, 
R9A, F10A, V16A, and Y18A were found to demonstrate 
similar (same or less than) value of no peptide in the 
71 samples tested. These results suggest that the amino 
acid positions 7(R), 9(R), 10(F), 16(V), and 18(Y) within 
gp51p16-C may be common binding sites for anti-BLV 
antibodies.
Effect of alanine substitutions within gp51p16‑C in pBLV‑IF 
on viral expression and syncytia formation
The five common binding sites for BLV antibodies within 
the common epitope gp51p16-C were determined using 
a peptide ELISA. Interestingly, the gp51p16-C epitope is 
located in the N-terminal half of the mature BLV gp51 
protein that plays an important role in viral infectivity 
and syncytium formation [16–18]. To examine the effect 
Table 1 Japanese black cattle examined in peptide microarray
− BLV negative serum; + BLV positive serum
a Four BLV-negative Japanese Black calves (6–8-months-old) were experimentally challenged intravenously with white blood cells containing a proviral load of 
4 × 107 proviral copies, as determined by CoCoMo-qPCR-2 assay
b BoLA-DRB3 alleles were genotyped by PCR-SBT method and are according to the BoLA nomenclature committee of the Immune Polymorphism Database (IPD)-MHC 
database. Both alleles, A and B, for each experimental animal was shown
c White blood cells (WBCs) were measured at a single time point in all calves during the experiment
d Peripheral blood lymphocytes (PBLs) were measured at a single time point in all calves during the experiment
e Proviral load (expressed as the number of copies of provirus per 105 peripheral blood mononuclear cells) was evaluated using CoCoMo-qPCR-2 assay
f ELISA (enzyme-linked immunosorbent assay) to detect anti-BLV antibodies was performed using the BLV ELISA kit
Animal no.a BoLA‑DRB3b 
alleles A; B
Age (month) Sex WBCsc (cells/μl) PBLsd (cells/μl) Proviral loade  




BLV‑challenged BLV‑challenged BLV‑challenged BLV‑challenged
Before After Before After Before After Before After
JBS4 1601; 1601 8 ♂ 10,200 15,500 6560 11,100 0 67,284 − +
JBS6 1601; 1601 6 ♂ 9170 13,900 4690 9570 0 93,456 − +
JBN1 1501; 2703 6 ♀ 9060 8250 3084 4900 0 149 − +
JBN2 1501; 0503 6 ♀ 11,800 12,100 8142 9140 0 58,176 − +
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of the alanine mutations corresponding to five common 
binding sites for BLV antibodies on Env protein expres-
sion and syncytium formation, the infectious molecular 
clone pBLV-IF was used [37]. To verify the amino acid 
sequences of gp51p16-C that are encoded by pBLV-IF, 
the nucleotide sequence of the gp51 gene of pBLV-IF 
Table 2 The serums used in a new peptide ELISA high-throughput system
Serum samples were obtained from 647 BLV naturally infected cattle which were positive for anti-BLV antibodies and BLV provirus as determined by an anti-BLV ELISA 
kit and a BLV-CoCoMo-qPCR-2 assay, respectively, and 270 BLV non-infected cattle
a These BLV positive samples had 25 different BoLA-DRB3 alleles that were typed by PCR-SBT method
b These BLV negative samples had 23 different BoLA-DRB3 alleles, which 20 alleles of them were same with identification alleles on BLV positive samples as described 
above (b)
Local Farm  
no.
BLV positive samplesa BLV negative samplesb
Cattle no. BoLA‑DRB3 Cattle no. BoLA‑DRB3
No. Alleles No. Alleles
Aichi 2 32 12 0101, 0201, 0502, 0503, 0701, 0902, 1001, 
1101, 14011, 1501, 1601, 1801
5 6 0201, 0503, 1101, 1302, 1501, 1601
Ishikawa 1 12 7 0101, 0201, 0902, 1001, 1101, 1201, 1501 3 5 0601, 1101, 1201, 1501, 2703
Iwate 2 47 14 0101, 0201, 0502, 0503, 0701, 0902, 1001, 
1101, 1201, 14,011, 1501, 1601, 2703,  
4401
14 7 0503, 1001, 1101, 1201, 14011, 1501, 1601
Oita 2 30 13 0101, 0201, 0301, 0503, 0701, 0801, 0902, 
1001, 1101, 1302, 1501, 1601, 2703
8 7 0101, 0201, 0301, 1001, 1101, 1201, 2703
Osaka 2 52 12 0101, 0201, 0701, 0902, 1001, 1101, 1201, 
14011, 1501, 1601, 1801, 2703
2 4 0101, 1101, 14011, 1501
Okinawa 2 43 12 0101, 0201, 0502, 0503, 0701, 0902, 1001, 
1101, 1201, 14011, 1501, 1601
19 10 0101, 0201, 0503. 0701, 1001, 1101, 1201, 
14011, 1501, 1601
Kagoshima 2 9 7 0502, 0503, 0701, 1001, 1302, 1501, 1601 28 10 0101, 0502, 0503, 0801, 1001, 1101, 1201, 
1302, 14011, 1501, 1601, 2703
Kanagawa 2 55 11 0101, 0201, 0701, 0902, 1001, 1101, 1201, 
14011, 1501, 1801, 2703
10 8 0101, 0902, 1001, 1101, 1201, 14011, 1501, 
2703
Gifu 3 67 17 0101, 0201, 0501, 0502, 0503, 0701, 0801, 
0902, 1001, 1101, 1201, 1302, 14011,  
1501, 1601, 1801, 2703
1 2 0101, 1001
Nagano 2 14 12 0101, 0501, 0502, 0901, 0902, 1001, 1101, 
1201, 14011, 1501, 1601, 1801
7 2 0101, 0902, 1001, 1101, 14011, 1601, 2703
Shiga 2 24 10 0101, 0601, 0902, 1001, 1101, 1201, 14011, 
1501, 1801, 2703
5 6 0101, 1001, 1101, 1201, 14011, 2703
Shizuoka 3 47 12 0101, 0201, 0503, 0901, 0902, 1001, 1101, 
1201, 14011, 1501, 1601, 2703
13 10 0101, 0502, 0503, 0701, 0902, 1001, 1101, 
1201, 1501, 1601
Hyogo 2 37 11 0101, 0201, 0902, 1001, 1101, 1201, 14011, 
1501, 1601, 1801, 2703
30 10 0101, 0201, 0901, 0902, 1001, 1101, 1201, 
14011, 1501, 1601, 1801, 2703
Chiba 2 45 13 0101, 0201, 0601, 0902, 1001, 1101, 1201, 
14011, 1501, 1601, 1701, 1801, 2703
16 12 0101, 0601, 0701, 0902, 1001, 1101, 1103, 
14011, 1501, 1701, 2703, 3201
Tokyo 1 16 6 0101, 1001, 1101, 14011, 1501, 1801 15 10 0101, 0902, 1001, 1101, 1201, 14011, 1501, 
1601, 1801, 2703
Nagasaki 2 22 11 0101, 0503, 0601, 0701, 0902, 1001, 1101, 
1201, 14011, 1501, 1601
43 16 0101, 0201, 0502, 0503, 0601, 0701, 0801, 
0902, 1001, 1101. 1201, 14011, 1501, 1601, 
2703, 3401
Niigata 2 42 15 0101, 0502, 0503, 0504, 0701, 0902, 1001, 
1101, 1201, 14011, 1501, 1601, 2002,  
2703, 3401
15 14 0101, 0502, 0503, 0701, 0902, 1001, 1101, 
1103, 1201, 1302, 14011, 1501 1601, 2802
Hokkaido 1 9 9 0101, 0201, 0502, 0503, 1001, 1201, 14011, 
1601, 3401
5 6 0502, 0503, 1001, 1201, 1501, 1601
Mie 1 3 4 0101, 1001, 1101, 1501 20 11 0101, 0201, 0503, 1001, 1101, 1201, 1302, 
14011, 1501, 1601, 1701
Yamagata 2 41 10 0101, 0502, 0503, 0701, 1001, 1201, 14011, 
1501, 1601, 2703
11 9 0201, 0502, 0701, 0801, 1001, 1101, 1201, 
1501, 1601
Total 38 647 270
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that corresponded to gp51p16-C was determined and 
compared with the reported sequences of the BLV cell 
line FLK-BLV strain pBLV913 (GenBank accession no. 
EF600696). Comparison of the sequences revealed that 
the gp51 gene of pBLV-IF exhibited a high degree of 
identity in the nucleotide sequence (99  %) and the pre-
dicted amino acid sequence (100 %) to the gp51 protein 
in the pBLV913 strain [41].
The codons at the positions 7, 9, 10, 16, and 18 within 
gp51p16-C were mutated to the codon for an alanine 
residue(s) to obtain mutant forms of pBLV-IF. To exam-
ine expression of cell-associated Env and Gag proteins by 
these various mutants, we transiently transfected 23CLN 
cells that strongly express BLV antigens after transfec-
tion with pBLV-IF [37] with either wild-type pBLV-IF, its 
variants, or a negative control vector together with GFP 
expression vector pEGFP-N1 for normalization of the 
efficiency of transfection. Twenty hours following trans-
fection, a fraction of 23CLN cells were harvested and 
GFP-expressing cells were analyzed by flow cytometry. 
Fig. 1 Results of the analyses of gp51p16‑C with BLV positive serum. These experiments were performed by a new high‑throughput peptide ELISA 
system. a The define line of positive response. The line represents a positive response with an OD value of 0.3 that was determined in accordance to 
histogram analysis using 270 BLV negative and 647 BLV positive serums as described above Table 2. The average and standard deviation of negative 
samples were 0.12 and 0.16, and postive samples were 0.96 and 0.54, respectively. b The response of gp51p16‑C with positive serum from 647 cattle 
naturally infected with BLV by ELISA. Serum samples collected from cattle naturally infected with BLV were observed to have different levels of pro‑
viral loads and shared 25 different BoLA‑DRB3 alleles. c Positive population of 647 serum samples from BLV naturally infected cattle with gp51p16‑C
Page 6 of 14Bai et al. Retrovirology  (2015) 12:106 
Thirty-six hours after transfection, the remaining 23CLN 
cells were lysed and lysates containing equal numbers 
of GFP-expressing cells were subjected to Western blot-
ting with anti-BLV Env and Gag proteins Mabs (Fig. 3a). 
Bands corresponding to the Env protein, gp51, and 
Gag protein, p24, of cell-associated BLV were specifi-
cally detected in cells that had been transfected with the 
mutated pBLV-IFs. The molecular mass of these proteins 
was similar to that of proteins detected in a lysate of FLK-
BLV cells that had been productively infected with BLV 
[42] as a positive control. In addition, two gp51 mutant 
proteins, namely, R7A and R9A, were expressed at levels 
similar to that of the wild type gp51 protein, while the 
levels of expression of the other three mutant proteins, 
namely F10A, V16A, and Y18A were less than that of the 
wild type protein. Likewise, the expression of Gag protein 
is the similar to that of gp51 expression (Fig. 3a).
We next investigated whether the mutant forms of 
pBLV-IF comprise a fusion capacity, one of the cyto-
pathic effects of BLV Env in 293T cells, which are able 
to induce formation of multinucleated cells. pBLV-IF 
and the mutated pBLV-IFs, or a negative control vector, 
combined with the GFP expression vector pEGFP-N1, 
were expressed in 293T cells, and GFP positive cells were 
visualized by confocal laser scanning microscopy. GFP 
was used as the reporter molecule for discrimination 
between transfected and untransfected cells. The results 
of a typical experiment are depicted in Fig. 3b. A fraction 
of the GFP positive cells with the single alanine mutated 
pBLV-IFs, R7A, R9A, F10A, V16A, and Y18A, showed an 
ability to form syncytium in addition to transfectant with 
wild-type pBLV-IF. By contrast, GFP positive cells trans-
fected with the control vector were not observed to form 
syncytium.
These results demonstrate that the R7A and R9A muta-
tions at common binding sites to BLV antibodies did 
not affect the synthesis, processing, and expression of 
viral proteins, and fusogenicity following transfection. 
F10A, V16A, and Y18A decreased the expression of gp51 
protein.
Distribution of polymorphic and conserved amino acid 
residues in gp51p16‑C
To investigate the conservation of each amino acid resi-
due within gp51p16-C between the BLV strains, the 
nucleotide sequences of 517 BLV strains were collected 
from GenBank and analyzed for the conservation of each 
amino acid and frequencies of binding amino acid within 
the common epitope gp51p16-C (Fig. 3c). Two (positions 
7 and 10) of five common binding sites to BLV antibod-
ies within the common epitope gp51p16-C were found 
to be highly conserved as there were no mutations at the 
amino acid positions 7 and 10 in the 517 BLV strains. The 
remaining three (positions 9, 16, and 18) were found to 
be polymorphic and the frequency was 0.99.
Discussion
In this study, from 156 synthetic peptides encompass-
ing the Gag and Env gp51 proteins, one B cell epitope, 
gp51p16, was recognized by all four cattle experimentally 
Fig. 2 Response of BLV positive serum with single alanine variants of gp51p16‑C. These experiments were performed by a new high‑throughput 
peptide ELISA system. a Sequences of the gp51p16‑C peptide and its variants with single alanine mutations are shown in the single‑letter amino 
acid code, and alanine mutation sites are represented in red. b The stimulation index (SI) of four BLV positive serum samples was obtained from 
cattle experimentally infected with BLV (JBS4, JBS6, JBN1, and JBN2) for individual variants. c Reactions of the serum samples obtained from cattle 
naturally infected with BLV for individual variants
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infected with BLV using a peptide microarray. The 
sequence of gp51p16 was PPQGRRRFGARAMVT. 
Serums from 647 cattle naturally infected with BLV that 
shared 25 different BoLA-DRB3 alleles were used to 
examine the positive response of 20-mer gp51p16-C that 
comprised the entire length of the original gp51p16 (15-
mer) and cysteine of C-terminal. Interestingly, gp51p16-
C responded to 590 (91.2 %) of 647 serum samples. The 
corresponding sequence was WPPPQGRRRFGARAM-
VTYDC, indicating that gp51p16-C contains a common 
B cell epitope. In a previous study [17], synthetic pep-
tides corresponding to the BLV gp51 protein were used 
to analyze B cell neutralizing and T helper cell epitopes, 
and the following epitopes were identified: Peptide 64–73 
(RRRFGARAMV), 98–117 (SQADQGSFYVNHQILFL-
HLK), and 177–192 (PDCAICWEPSPPWAPE). Using 
rabbit serum, these were determined to be B cell neu-
tralizing epitopes and Env pep61 epitope (PQGRRRF-
GARAMVTYDCE) was identified as a sequence capable 
of inducing T cell proliferation or mitogenicity in mice 
[27, 28]. In particular, the common B cell epitope identi-
fied in this study contained the whole B cell neutralizing 
epitope 64–73 that had been previously found in rabbit 
[17] and the majority of the Env pep61 epitope that had 
been previously identified in mice [27, 28]. Although a 
striking feature of gp51p16-C was the response to over 
91.2  % of serum samples from naturally infected cat-
tle, 57 (8.8  %) of 647 serum samples showed very weak 
responses with gp51p16-C. Two helper T cell epitopes 
(169–188, LNQTARAFPDCAICWEPSPP; and 177–192, 
PDCAICWEPSPPWAPE) that had been previously iden-
tified in cattle and 177–192 (PDCAICWEPSPPWAPE) 
that had been recognized as a B cell neutralizing epitope 
in rabbit indicated that bovine T cell epitopes may com-
monly share identical sequences with B cell neutralizing 
Fig. 3 Effect of alanine substitutions in gp51p16‑C of pBLV‑IF on viral 
expression and fusogenicity, and conservation. After transfection, 
pBLV‑IF, mutated pBLV‑IFs with the single alanine mutations (R7A, 
R9A, F10A, V16A, and Y18A), or a negative control vector and the GFP 
expression vector pEGFP‑N1 were performed Western blotting (a) 
and syncytium (b) analyses. GFP was used as the reporter molecule 
for discrimination between transfected and untransfected cells. a For 
Western blotting, a fraction of 23CLN cells were harvested 20 h fol‑
lowing transfection and were analyzed for the ratio of GFP‑expressing 
cells by flow cytometry. The remaining 23CLN cells were lysed 48 h 
after transfection, and lysates with equal numbers of GFP‑expressing 
cells were subjected to Western blotting using anti‑BLV Env protein 
and anti‑Gag protein monoclonal antibodies and HRP‑conjugated 
goat antibodies. FLK‑BLV cells, which were productively infected with 
BLV, were used as the positive control. Positions of protein marker and 
BLV glycoprotein (gp51) were indicated and BLV Gag protein (p24). b 
For syncytium formation, 293T cells were visualized by confocal laser 
scanning microscopy. c Distribution of polymorphic and frequen‑
cies of antibody binding amino acid residues in gp51p16‑C. BLV 
nucleotide sequences (n = 517) were collected from GenBank, and 
amino acid sequences corresponding to gp51p16‑C were aligned. 
The amino acid positions 7, 9, 10, 16, and 18 are indicated by triangle. 
A single letter above gp51p16‑C sequences indicates a polymorphic 
amino acid residue
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epitopes [17]. We hypothesized that the common B cell 
epitope, gp51p16-C, produces BLV antibodies, and there-
fore, helper T cell immunity is primarily induced in vivo 
in animals that had no positive responses to gp51p16-C.
In our study, CD4+ T cell epitope mapping was per-
formed in Japanese Black cattle experimentally infected 
with BLV that carried different BoLA-DRB3 alleles, and 
CD4+ T cell epitopes (unpublished data) were identi-
fied that differed to those previously reported in mice, 
sheep, and cattle [17]. In addition, the recombinant vac-
cinia virus expressing Env vaccine had reduced the pro-
viral load in vaccinated sheep used as an experimental 
model, nonetheless it had not effected in cows [43, 44]. 
These results suggest that in addition to animal species, 
individual differences in cattle affect the BLV epitope. 
One important factor that induces individual differences 
is the polymorphism of MHC. Notably, the capacity of 
MHC class II molecules to deliver signals that anti-MHC 
class II Mabs may mediate several activities that include 
replacing T helper cells in the activation of B cells, 
thereby inducing the secretion of interleukin-1 in mono-
cytes [45]. Staphylococcal exotoxins provide a superan-
tigenic ‘bridge’ between T cell receptor molecules on T 
cells and MHC class II molecules on B cells, leading to 
B cell proliferation and immunoglobulin production that 
has been thought to trigger MHC-unrestricted interac-
tion between T cells and B cells, leading to the onset of 
autoimmunity [46]. Furthermore, the BoLA class II DRB3 
allele has been reported to be associated with BLV provi-
ral load [24]. One of the major challenges of the present 
study was the use of a large sample size of cattle with var-
ied genetic backgrounds in BoLA-DRB3 for the success-
ful identification of a common B cell epitope.
The common B cell epitope is an important target for 
antibody production and vaccine antigens. Antibodies 
directed against peptide 64–73 (RRRFGARAMV) that 
are identical to most of gp51p16-C corresponding to 
the HTLV-I gp46 sequence (peptide 88–98; WTKIKP-
NRNGGGJ) were previously demonstrated to possess a 
neutralizing character [17, 47]. Therefore, we determined 
the binding sites to BLV antibodies within gp51p16-C 
using single alanine variants and serum from 71 cattle 
naturally infected with BLV. The common binding sites of 
gp51p16-C R(7), R(9), F(10), V(16), and Y(18) were identi-
fied. Importantly, two regions (peptides 64–73 and 78–92) 
of the BLV Env protein are included in the small domain 
forming the junction between the stem and the large glob-
ular head [48]. Therefore, the five antibody binding sites 
identified within gp51p16-C were considered as amino 
acids essential for the expression of the BLV Env protein.
Epitope antibodies may mediate inhibition of BLV-
induced syncytium formation [17]. Several variants of 
BLV Env proteins have been reported as failing to induce 
syncytia resulting in sustained substitution of an amino 
acid conserved at analogous positions in the HTLV-1 
Env protein [49]. Moreover, the peptide 64–73 that was 
found to be completely identical to most of gp51p16-C, 
had been previously reported to be adjacent to residue 
62, which was located in epitope F of BLV gp51, may 
be linked to syncytium formation induced by BLV Env 
[17], and antisera raised against peptide 64–73 com-
pete with Mab F recognition in an ELISA [16]. Hence, 
we examined whether the antibody binding sites identi-
fied within the common B cell epitope affect Env expres-
sion and cell fusion by reverse genetics of the infectious 
molecular clone pBLV-IF. R7A and R9A mutations were 
not observed to affect Env protein expression and syncy-
tium formation. Likewise, in recently report [50], muta-
tion of a single Env N-linked glycosylation site have not 
decreased pathogenicity of BLV has been reported. By 
contrast, F10R, V16A and Y18A have a little reduced the 
expression of gp51 proteins.
The Env protein strain-specific substitution Y108H, 
corresponding to Y18 in the gp51p16-C determined in 
the present study, has been exposed on the front face 
of the BLV receptor binding domain (RBD) [49]. In this 
study, this site was found to be polymorphic. The remain-
ing binding sites were predicted to be exposed on the 
front face of BLV RBD. Furthermore, the amino acid 
positions 7 (R) and 10 (F) of gp51p16-C are highly con-
served, indicating that they may be essential for unknown 
viral functions.
It is well known that pathogens may easily escape host 
immune recognition and may result in species-specific 
responses in humans and animals. The results reported 
in this study are not only of fundamental biological inter-
est, but also of practical importance. This is the first study 
to report the presence of a common B cell epitope in BLV 
gp51 that is recognized by cattle with overlapping BoLA-
DRB3 alleles. BLV gp51 was characterized by an amino 
acid mutation of several BLV antibody binding sites that 
R7A and R9A were not found to have an effect on gp51 
protein expression and fusogenicity. The remaining three 
antibody binding sites, F10A, V16A, and Y18A related 
with the reduction of expression of gp51 protein, not yet 
affect the syncytium formation. Therefore, the common 
B cell epitope gp51p16-C is the optimal target for the 
production of Mab, antigen for BLV vaccine design, and 
immunodiagnostic tests.
Conclusions
One common B cell epitope, gp51p16, was identified by 
epitope mapping for 20-mer overlapping peptides of p12, 
p24, p15 and gp51 proteins. Gp51p16-C, which contains 
whole sequence of gp51p16 and C-terminal cysteine, was 
recognized common B cell epitope that showed 91.2  % 
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positive response in a comprehensive screening of 647 
BLV naturally infected cattle carrying 25 different BoLA-
DRB3 alleles. Furthermore, it contains five common 
antibody binding sites (amino acids R7, R9, F10, V16, 
and Y18) and which two common (R7 and F10) antibody 
binding sites were highly conserved. R7A and R9A have 
no effect on the expression and all of five antibody bind-
ing sites have no effect fusogenicity of BLV gp51 protein. 
The B cells of immune system plays an important role in 
preventing and suppressing the progression of disease 
caused by BLV. Thus, common B cell epitope, gp51p16-
C, is particularly important to provide a useful target 
for monoclonal antibody production, antigens for the 
diagnosis of BLV infection, BLV vaccine strategies, and 
becomes a significant implication for disease control and 
diagnosis.
Methods
Animals, serum, and DNA extraction
For peptide microarray, serum samples were obtained 
from four Japanese Black cattle experimentally infected 
with BLV prior to infection and 21 weeks following BLV 
infection. BLV negative and positive serum samples were 
also obtained (Table  1). Blood samples were collected 
for a period of 10 weeks following inoculation, and DNA 
was extracted to measure proviral loads using the BLV-
CoCoMo-qPCR-2 assay as previously described [51–54] 
(Table 1). BLV infection was examined using an anti-BLV 
antibody ELISA kit (JNC Inc., Tokyo, Japan) (Table  1). 
This study was approved by the local Animal Ethics Com-
mittee and the Animal Care and Use Committee of the 
Animal Research Center, Hokkaido Research Organiza-
tion (approval number 1302). Furthermore, 647 BLV pos-
itive serum samples and 270 BLV negative serum, which 
were collected from 38 farms in 21 provinces in Japan 
used for this study (Table 2).
Identification of BoLA‑DRB3 by polymerase chain 
reaction‑sequence‑based typing (PCR‑SBT)
BoLA-DRB3 alleles were typed using the PCR-SBT 
method as previously described [55].
B cell epitope mapping using peptide microarray
The PepStar peptide microarrays were provided by JPT 
Peptide Technologies (Berlin, Germany) [56]. A library 
was constructed of 156 overlapping peptides compris-
ing 15-mer peptides with an offset of four amino acids 
that were derived from mature peptides encoded and 
expressed in gag and env, the BLV Gag proteins, p12, 
p24, and p15 corresponding to the reported sequences 
of BLV Gag (GenBank accession no. LC057268), and 
BLV Env gp51 corresponding to the reported sequences 
of Env (GenBank accession no. EF600696). The primary 
sequence of the amino acid positions (Table 3) was com-
mercially synthesized using the PepStar technique. The 
synthesized peptides were displayed in three identical 
subarrays on each slide. The peptide microarray slide and 
glass cover were prepared for the microarray sandwich 
and blocked with Sea Block Blocking Buffer (Thermo 
Fisher Scientific, Rockford, IL). After blocking, the micro-
array sandwich was washed in Tris-buffered saline (TBS-
buffer pH 7.4; 0.2 M NaCl, 5.5 mM KCl, and 0.02 M Tris), 
and serum was placed between the two slides and incu-
bated for 2 h. To remove excess antibody, the microarray 
sandwich was washed as described above followed by the 
addition of secondary antibody (Alexa Fluor 647-con-
jugated Goat Anti-Bovine IgG (H  +  L); Jackson Immu-
noResearch Laboratories Inc., West Grove, PA, USA). The 
slide was washed, centrifuged to dry, and scanned using a 
Microarray scanner (GenePix 4000B, Molecular Devices, 
Sunnyvale, CA, USA). Positive and negative controls were 
obtained from BLV-infected and BLV-uninfected cat-
tle, respectively. Fluorescent signals were acquired with 
a microarray scanner at a resolution with a pixel size of 
10 μm. Signals obtained were normalized and plotted to 
reflect the relative intensities of the fluorescence signals.
Synthetic peptide containing a C‑terminal cysteine, and a 
new high‑throughput peptide ELISA system
A C-terminal cysteine-containing peptide (gp51p16-C) 
that contained the B cell epitope gp51p16 and its 17 vari-
ants (Fig.  2a) was synthesized and purified using high-
pressure liquid chromatography (HPLC) to  >70  % purity 
(Scrum. Inc., Tokyo, Japan). A new high-throughput pep-
tide ELISA system was designed using cysteine-containing 
peptides to allow crosslinking with maleimide-activated 
carrier protein and mariculture keyhole limpet hemocya-
nin (mcKLH) (Thermo Fisher Scientific) to fix the peptide 
on the microplate well surface [57]. Briefly, mcKLH was 
dispensed into a 96-well flat bottom microplate (Sumi-
tomo Bakelite Co., Ltd. Tokyo, Japan) and incubated over-
night at 4  °C. The microplate was extensively washed in 
phosphate buffered saline (PBS) containing 0.05 % Tween 
20 (PBS-T). The C-terminal cysteine-containing peptide 
was dissolved in maleimide conjugation buffer [83  mM 
sodium phosphate buffer (pH 7.2) containing 0.1 M EDTA, 
0.9 M NaCl, and 0.02 % sodium azide] and added to the 
wells of the microplate. After incubation, the microplate 
was washed and blocked with PBS-T containing 10  % 
horse serum (Gibco, Grand Island, NY, USA). To absorb 
non-specific antibodies prior to add into microplate, the 
500-fold diluted serum sample was mixed with 200  μg/
ml KLH (Sigma, St. Louis, MO, USA), 20 μg/ml mcKLH 
and 10 % horse serum at 37 °C at least 30 min. After wash-
ing, peroxidase-conjugated Affinipure goat anti-bovine 
IgG (H + L) (Jackson ImmunoResearch Laboratories Inc.) 
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was added to each well, and the microplate was read at an 
optical density (OD) of 450 nm with a microplate reader 
(EnSight; PerkinElmer, Yokohama, Japan). The cut-off line 
value was determined in accordance to histogram analysis 
using BLV negative and positive serum samples. All tests 
were set up in triplicate. The measured OD of the samples 
was compared with that of control wells incubated without 
peptide. The stimulation index (SI) was calculated using 
the following formula:
Cell culture and transfection
Human embryonic kidney 293T cells, 23CLN cells, and 
FLK-BLV cells that had been productively infected with 
BLV [42] were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM, Gibco) supplemented with penicillin, 
streptomycin, and glutamine (PSG, Gibco), and 10 % fetal 
bovine serum (FBS, Sigma). 293T cells (3 × 105 cells) and 
23CLN cells (5 × 105 cells) were transfected with 3.6 and 
7.6 μg of pBLV-IF [58], an infectious molecular clone of 
BLV with two copies of the long terminal repeat (LTR) 
and full-length BLV provirus, mutated pBLV-IFs, respec-
tively, or a negative control vector [pBluescript II (KS-)] 
(Stratagene, La Jolla, CA), and 0.4 μg of pEGFP-N1 [59] 
using 12  μl of FuGENE HD (Promega, Madison, WI, 
USA) for 293T cells or 32 μl for 23CLN cells.
Construction of mutant pBLV‑IF
Alanine mutations were introduced into the env gene of 
pBLV-IF by site-directed mutagenesis. The 3′-half of the 
pBLV-IF sequence was cloned into a pBluescript II (SK-) 
vector using HindIII and KpnI restriction enzyme sites, and 
the plasmid was subjected to site-directed mutagenesis by 
PCR using PrimeSTAR GXL (Takara Bio, Otsu, Japan) as 
follows: 98 °C for 2 min, followed by 25–30 cycles of 98 °C 
for 15 s, and 68 °C for 90 s. The primer pairs used to gen-
erate the alanine mutations are described in Table 4. Each 
3′-half of pBLV-IF encoding the alanine mutation in the env 
sequence was digested with the restriction enzymes Hin-
dIII and BmgBI, and each DNA fragment was cloned into 
the corresponding region of pBLV-IF in full-length.
Stimulation index =
gp51p16-C or variant peptides
no peptide
Syncytium formation assay
Thirty-six hours following transfection, 293T cells were 
cultured and syncytium formation was determined. The 
cells were visualized using the confocal laser scanning 
microscope FV1000 (Olympus, Tokyo, Japan).
Flow cytometer and Western blotting
A fraction of the 23CLN cells were harvested 20  h post-
transfection, and the ratio of GFP-expressing cells was 
determined using a FACSCalibur™ flow cytometer (BD 
Japan, Tokyo, Japan). Data were analyzed using FCS Express 
(version 3; De Novo Software, Los Angeles, CA, USA). The 
remaining 23CLN cells were lysed 48 h following transfec-
tion, and lysates with equal numbers of GFP-expressing cells 
were subjected to Western blotting with an anti-BLV Env 
protein monoclonal antibody (Mab) (BLV-2; VMRD, Pull-
man, WA, USA) and an anti-BLV Gag protein Mab (BLV-
3; VMRD, Pullman, WA, USA) followed by incubation with 
HRP-conjugated goat anti-mouse IgG (Amersham Biosci-
ence, Piscataway, NJ) as previously described [60].
Analysis of sequences
Amino acid sequences were downloaded from the Gen-
Bank database and aligned using the MEGA software 
version 6.06 [61].
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